Aquinox Pharmaceuticals (AQXP) Downgraded by Zacks Investment Research to “Hold”
Zacks Investment Research cut shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) from a buy rating to a hold rating in a report released on Friday.
According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “
Several other brokerages have also weighed in on AQXP. ValuEngine lowered Aquinox Pharmaceuticals from a hold rating to a sell rating in a report on Friday, September 15th. Canaccord Genuity set a $22.00 price objective on Aquinox Pharmaceuticals and gave the company a buy rating in a report on Tuesday, December 19th. Cantor Fitzgerald reissued a buy rating and issued a $28.00 price objective on shares of Aquinox Pharmaceuticals in a report on Thursday, November 9th. Finally, Needham & Company LLC reissued a buy rating and issued a $25.00 price objective on shares of Aquinox Pharmaceuticals in a report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. Aquinox Pharmaceuticals currently has an average rating of Hold and a consensus target price of $22.00.
Large investors have recently bought and sold shares of the company. Investment Centers of America Inc. bought a new position in shares of Aquinox Pharmaceuticals during the third quarter valued at approximately $175,000. Citadel Advisors LLC bought a new position in shares of Aquinox Pharmaceuticals during the third quarter valued at approximately $194,000. Bank of New York Mellon Corp grew its holdings in shares of Aquinox Pharmaceuticals by 16.5% during the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock valued at $327,000 after purchasing an additional 3,299 shares during the last quarter. Sphera Funds Management LTD. grew its holdings in shares of Aquinox Pharmaceuticals by 21.7% during the third quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock valued at $1,072,000 after purchasing an additional 13,450 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Aquinox Pharmaceuticals by 3.3% during the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock valued at $1,171,000 after purchasing an additional 2,691 shares during the last quarter. 96.25% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Aquinox Pharmaceuticals (AQXP) Downgraded by Zacks Investment Research to “Hold”” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2018/01/13/aquinox-pharmaceuticals-aqxp-downgraded-by-zacks-investment-research-to-hold.html.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related stocks with our FREE daily email newsletter.